Trials / Unknown
UnknownNCT05498597
AMT-151 in Patients With Selected Advanced Solid Tumours
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Multitude Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.
Conditions
- Advanced Solid Tumor
- Advanced Cancer
- Advanced Carcinoma
- Ovarian Cancer
- Ovarian Carcinoma
- Ovarian Epithelial Cancer
- Ovarian Endometrioid Adenocarcinoma
- Endometrial Cancer
- Endometrial Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Clear Cell Adenocarcinoma
- Lung Adenocarcinoma
- Triple Negative Breast Cancer
- Pancreatic Ductal Adenocarcinoma
- Malignant Pleural Mesothelioma
- Ovarian Clear Cell Carcinoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMT-151 | Administered intravenously |
Timeline
- Start date
- 2023-01-25
- Primary completion
- 2024-01-01
- Completion
- 2024-10-30
- First posted
- 2022-08-12
- Last updated
- 2023-10-19
Locations
9 sites across 2 countries: Australia, China
Source: ClinicalTrials.gov record NCT05498597. Inclusion in this directory is not an endorsement.